

## Index

- A1C, S5, S8, S11, S12, S20, **S21–S22**, S97–S99  
 advantages of, S21  
 age and, S21–S22  
 cardiovascular disease and, S102–S103  
 CGM technology effect on, S106, S112, S115–S116  
 confirming diagnosis with, S22  
 correlation with BGM, S98  
 hemoglobinopathies and, **S22**  
 in children, S98–S99, S235–S237, S241–S242  
 in hospitalized patients, S268  
 in older adults, S219, S220, S223  
 in people with HIV, **S28**  
 in screening children, **S28**  
 limitations, **S98**  
 microvascular complications and, S101–S102  
 other conditions affecting, **S22**  
 point-of-care assays, S5, S21, S98  
 in prediabetes, S24–S25  
 in pregnancy, S256, **S257–S258**  
 race/ethnicity and, **S22**, S98–S99  
 recommendations, **S21**  
 setting and modifying goals for, S103–S104
- acarbose, S136, S152  
 access to care, S13  
 access, to insulin, S279  
 ACCORD study, S57, S170, S218  
 ACE inhibitors, S53, S54, S163, S164–S165, S192, S194, S196, S238, S239, S244, S255, S261  
 acute kidney injury, S134, S161, S162, **S165**, S177, **S194**, S272  
 ADA consensus reports, S4, S70, S78, S106, S217  
 ADA evidence-grading system, S3  
 ADA Professional Practice Committee, S1, S4  
 ADA scientific reviews, S4  
 ADA statements, S4  
 ADAG study, S98, S104, S105  
 Addison disease, S23, S56, S237  
 adolescents. *see* children and adolescents.  
 adrenal insufficiency, primary, S56, S237  
 adult-onset diabetes. *see* Type 2 diabetes.  
 adults, prediabetes and diabetes screening in, S25, S27–S28  
 ADVANCE trial, S103, S105, S160  
 advocacy statements, S7, **S279–S280**  
   care of young children with diabetes in the childcare setting, S280  
   diabetes and driving, S280  
   diabetes and employment, S280  
   diabetes care in the school setting, S279–S280  
   insulin access and affordability, S279
- affordability, of insulin, S279  
 Affordable Care Act, S13  
 African Americans, S22, S23, S24, S25, S27, S77, S105, S193  
   A1C variability in, S98–S99  
   ADA risk test for, S26  
   BMI cut point in, S28
- age  
   aspirin use and, S171  
   effect on A1C, **S21–S22**  
   to start screening for diabetes, S24, S27  
   risk factor for diabetes, **S27**  
   statin treatment and, S167
- agricultural workers, migrant, S13  
 AIM-HIGH trial, S170  
 albiglutide, S181, S182  
 albuminuria, S7, S75, S79, S105, S148, S159, S161, S164, S165, S171, S176, S182, S183, S191, S192, **S193**, S194, S195, S196, S197, S198, S199, S237, S239, S240  
 alcohol intake, S54, S57, S72, **S76**, S106, S117, S136, S163, S169, S207, S246, S255  
 algorithms, insulin dosing, using machine learning, S9, S268  
 alirocumab, S168  
 alogliptin, S148, S152, S173, S183, S270  
 alpha-glucosidase inhibitors, S44, S131, S152  
 alpha-lipoic acid, **S208**  
 ambulatory glucose profile (AGP), S100  
 amputation, foot, S177, S206, S209, S210, S211, S212  
 analogs. *see* insulin analogs.  
 angiotensin receptor blockers (ARBs), S7, S53, S54, S147, S163, S164–S165, S191–S192, S194, S231, S238  
 anti-VEGF agents, **S205–S206**  
 antiplatelet agents, **S170–S172**  
 antipsychotics, atypical, S26, S28, S84  
 antiretroviral therapies, S24, S28  
 anxiety disorders, S82, S136  
 ARRIVE trial, S171  
 ASCEND trial, S75, S171, S172  
 Asian Americans, S23, S24, S25, S26, S27, S28, S43, S129, S130, S132, S135  
 aspart, S29, S141, S153, S222  
 aspirin therapy, S170, **S171–S172**, S205, S219  
 ASPREE trial, S171  
 atenolol, S208, S261  
 atherosclerotic cardiovascular disease (ASCVD), **S158–S190**  
 atorvastatin, S167  
 atypical antipsychotics, S26, S28, S84  
 autoimmune diseases, S23, **S57**, **S237**  
 automated insulin delivery (AID) systems, S6–S7, S111, S112, S115, **S118–S119**, S141  
 autonomic neuropathy, diabetic, S8, **S78**, S160, S206, **S207**, S273
- balloons, implanted gastric, S132  
 bariatric surgery. *see* metabolic surgery.  
 basal insulin, S9, **S113–S114**, S116, S119, S140, S141, S150, **S151**, S152, S153, S154–S145, S222, S224, S226, S233, S269, S270, S271, S272, S273  
 bedtime dosing  
   of antihypertensives, S165  
   of insulin, S144–S145, S150, S220, S222, S235  
 behavior changes, S6, S12, **S68–S96**  
   diabetes self-management education and support, **S68–S70**  
   for diabetes prevention, **S42–S43**  
   medical nutrition therapy, **S68–S76**  
   physical activity, **S76–S78**  
   in gestational diabetes, **S258**  
   psychosocial care, **S79–S86**  
   smoking cessation, **S79**  
   for weight loss, S130–S131
- bempedoic acid, **S169**  
 beta-carotene, S6, S72, S76  
 beta-cell replacement therapy, S142, S146  
 biguanides, S152  
 bladder dysfunction, S207, S256  
 Blood Glucose Awareness Training, S82, S106  
 blood glucose monitoring (BGM), S50, S75, S79, S97, S104, **S111–S114**, S144–S145, S243  
   in hospitalized patients, **S269**  
   continuous glucose monitoring, **S99–S101**  
   correlation with A1C, S98  
   devices for, **S111–S127**  
   during pregnancy, S257  
   in hypoglycemia, S104, S106  
   in intensive insulin regimens, **S113**  
   in people on basal insulin, oral agents, or noninsulin injectables, **S113–S114**  
   in schools, S112  
   initiation of, S112  
   meter standards, **S113**  
   optimizing, **S113–S114**  
 blood pressure control. *see also* hypertension, S8, **S159–S165**, S191, S195, **S208**, S224, S225  
 body mass index (BMI), S9, S24–S25, S43, S44, S45, S53, S76  
   COVID-19 mortality and, S60  
   effects of metformin use in pregnancy on, S259  
   ethnicity and, **S27–S28**  
   for medical weight loss medications, S132  
   for metabolic surgery, S132, S135, S243, S244  
   in obese patients, S129–S130  
   in screening children, S240–S241  
   postpartum, S262  
 bone fracture risk, S44, S45, S60, S148  
 bone-strengthening activities, S76, S77, S233, S241, S242  
 bromocriptine, S152
- calcium channel blockers, S164, S165, S196  
 canagliflozin, S151, S152, S177, S178, S179, S181, S182, S183, S197  
 cancer, risk in diabetics, **S56–S57**  
 CANVAS study, S177, S178, S179, S182, S197, S199  
 capsaicin, topical, **S208**  
 carbamazepine, **S208**  
 carbohydrate intake, S14, S21, S24, S42, S72, **S73–S75**, S78, S104, S136, S140, S142, S144–S145, S225, S233–S234, S257, S258, S259, S271, S272  
 cardiac autonomic neuropathy, diabetic, S206, **S207**  
 cardiac function testing, **S245–S246**  
 cardiovascular disease, S2, S7, **S158–S190**  
   A1C and outcomes of, S102–S103  
   antiplatelet agents, **S170–S172**  
   cardiac testing, **S176**  
   hypertension/blood pressure control, **S159–S165**  
   lifestyle and pharmacologic interventions, **S176–S184**

- lipid management, **S165–S166**  
 prevention of, **S44–S45**, S224  
 screening, S172, **S176**  
 statin treatment, **S165–S170**  
 treatment, **S172–S176**
- cardiovascular risk, S13, S15, S25, S27, S31, S44, S45, S76, S78, S101, S102, S129, S135, S143, S158, S159, S160, S162, S166, S167, S169, S172, S176, S180, S184, S193, S194, S195, S197, S207, S218–S219, S238  
 risk calculator, **S159**
- care delivery systems, S11–S13  
 access to care and quality improvement, S13  
 behaviors and well-being, S12  
 care teams, S12  
 chronic care model, S11  
 medication cost considerations, S12  
 six core elements, S11  
 system-level improvement strategies, S11–S12  
 telehealth, S12
- care teams, S12
- CARMELINA trial, S173, S182
- CAROLINA trial, S173, S177
- celiac disease, S23, S56, S231, **S237–S238**
- CHAP trial, S7, S9, S164, S261
- Charcot neuropathy, S78, S209, S211
- childcare, S233, S279, S280
- children and adolescents, S7, S8, **S230–S253**, S279–S280  
 A1C in, S98–S99, S235–S237, S241–S242  
 asymptomatic, risk-based screening in, S25  
 cystic fibrosis-related diabetes in, **S28–S29**  
 diabetes care in childcare settings, S233, S279, S280  
 diabetes care in school setting, S112, S234, S279–S280  
 insulin pumps in, S119  
 maturity-onset diabetes of the young (MODY), S19, **S28–S29**, S30  
 monogenic diabetes syndromes, S19, S30–S32  
 neonatal diabetes, S19, S30, S31  
 physical activity in, S76, S77  
 screening for type 1 risk, S24–S25  
 screening for prediabetes and type 2, S25, S28  
 transition from pediatric to adult care, **S246**  
 type 1 diabetes in, **S233–S240**  
 type 2 diabetes in, **S240–S246**
- China Da Qing Diabetes Prevention Outcome Study, S45
- CHIPS trial, S163, S261
- cholesterol lowering therapy, S7, S53, S166, S167, **S168–S169**
- chronic care model, S11
- chronic kidney disease, diabetic, S8, **S191–S202**  
 acute kidney injury, **S194**  
 assessing albuminuria and GFR, **S193**  
 diagnosis, **S193–S194**  
 epidemiology, **S193**  
 interventions for, **S195–S199**  
 referral to nephrologist, **S199**  
 risk of progression, S191, S193  
 screening recommendations, **S191**  
 staging, S194  
 surveillance, S194–S195  
 treatment recommendations, **S191–S183**
- classification, S5, **S19–S20**
- clonidine, S208, S261
- clopidogrel, S170
- closed-loop systems, S105, S119, S144  
 do-it-yourself, **S120**  
 hybrid, S141, S218, S234, S260
- coaching, online, S69, S120
- cognitive capacity/impairment, S80, **S84–S86**
- colesevelam, S152
- collaborative care, **S49–S51**
- collagen vascular diseases, S56
- combination therapy, S7, S143, S144, S146, S147, S149, S150–S151, S154, S161, S168, S168–S169, S169–S170, S208, S222
- community health workers, S5, S13, S15, S43, S70, S79
- community screening, **S28**
- community support, S15
- comorbidities, S10, S11, **S56–S60**  
 assessment of, S6, **S49–S67**  
 autoimmune diseases, S23, **S57, S237**  
 cancer, **S56–S57**  
 cognitive impairment/dementia, **S57**  
 COVID-19, **S60–S62**  
 fractures, S148, S161, S177, S222, S223  
 nonalcoholic fatty liver disease, **S57–S60**  
 obstructive sleep apnea, **S60**  
 periodontal disease, **S60**  
 prevention or delay of, S5, **S41–S48**
- COMPASS trial, S172, S283
- computerized prescriber order entry (CPOE), S9, S267, S268
- CONCEPTT study, S257, S258
- connected insulin pens, S112, S117–S118, S236
- continuous glucose monitoring (CGM), S6, S7, S8, S9, S50, **S114–S117**  
 ambulatory glucose profile in, S99, S100, S101  
 assessment of glycemic control, S97, S98, S99–S101  
 devices for, **S114–S117**  
 in hospitalized patients, S269, S271, S272  
 in hypoglycemia prevention, S106  
 in older adults, S218  
 in pediatric type 1 diabetes, S99, S112, S234, S236  
 in pediatric type 2 diabetes, S243  
 in pregnancy, S116, S258  
 interfering substances, S117  
 intermittently scanned devices, S106, S114–S115, S116, S235, S236, S241, S258  
 side effects, S116–S117  
 standardized metrics for, S99
- continuous subcutaneous insulin infusion (CSII), S140–S141
- coronary artery disease, S78, S164, S165, S172, S176
- cost considerations, S11, **S12**, S13  
 glycemic control, S9, S148, S221, S222  
 insulin therapy, S117, S119, S141, S150, S151, S153, S260, S279  
 metabolic surgery, S135  
 weight loss medications, S132–S134, S151
- Counterfeit test strips, S113
- COVID-19, S7, **S60–S62**, S129, S269
- COVID-19 vaccines, S6, S51, **S56**
- CREDESCENCE study, S177, S178, S179, S182, S197, S198
- cystic fibrosis-related diabetes, S19, **S28–S29**
- DAPA-CKD study, S177, S178, S179, S197, S198
- DAPA-HF study, S178, S179, S180, S182
- dapagliflozin, S62, S151, S152, S177, S178, S180, S181, S182, S183, S197
- DARE-19 study, S62
- DASH diet, S42, S163, S166
- DECLARE-TIMI 58 study, S177, S178, S179, S182, S197, S198
- degludec, S141, S151, S152, S153, S154, S222
- delay, of type 2 diabetes, S5–S6, **S41–S48**  
 lifestyle behavior change, **S42–S43**  
 person-centered care goals, **S45–S46**  
 pharmacologic interventions, **S43–S44**  
 recommendations, S41, S42, S43–S44  
 of vascular disease and mortality, **S44–S45**
- DELIVER study, S178, S179, S180, S182
- dementia, in diabetics, S57, S84, S105, S170, S217–S218
- dental practices, screening in, S28
- depression, S14, S53, S80, S81, **S82–S83**, S119, S133, S136, S208, S216, S217, S220, S223, S235, S246
- detemir, S144, S151, S153, S222
- devices. *see* technology.
- Diabetes Control and Complications Trial (DCCT), S21, S101, S102, S103, S104, S119, S140, S141, S236, S240
- Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S8, S102, S103, S105, S218
- diabetes distress, S6, S14, S80, **S81–S82**, S83, S115, S235, S246, S274
- diabetes medical management plan (DMMP), for students, S112
- Diabetes Prevention Impact Tool Kit, S43
- Diabetes Prevention Program (DPP), S25, S27, **S42**, S43, S44, S75, S120, S149  
 delivery and dissemination of, S43
- Diabetes Prevention Recognition Program (DPRP), S43
- diabetes self-management education and support (DSMES), S6, S7, S12, S15, S50, **S68–S70**, S71, S82, S150
- diabetes technology. *see* technology, diabetes.
- diabetic ketoacidosis, S20, S60, S61, S77, S81, S106, S116, S141, S142, S148, S177, S224, S233, S243, S256, S260, **S273**
- diabetic kidney disease. *see also* chronic kidney disease.  
 dietary protein and, S75  
 diagnosis, S193–S194  
 exercise and, S79  
 finerenone in, S183–S184, S198–S199  
 glucose-lowering medications for, S196–S198  
 multiple drug therapy, S165
- Diabetic Retinopathy Study (DRS), S206
- diagnosis, S5, S6, **S19–S35**  
 confirmation of, S23  
 criteria for, S21  
 cystic fibrosis-related, S28–S29  
 diabetic kidney disease, S193–S194  
 diabetic neuropathy, S206–S207  
 diagnostic tests, S20–S22  
 gestational diabetes mellitus, S33–S35  
 monogenic diabetes syndromes, S30–S33  
 pancreatic, S33  
 posttransplantation, S30–S31  
 prediabetes, S25  
 type 1 diabetes, S22–S25

- type 1 vs type 2 in pediatric patients, S242  
type 2 diabetes, S25–S28
- diagnostic tests, S20–S22  
A1C, S21–S22  
age, S21–S22  
confirmation of, S22  
criteria for, S21  
ethnicity, S22  
fasting and 2-hr plasma glucose, S21  
hemoglobinopathies, S22  
race, S22
- diet, *see* Medical nutrition therapy.
- Dietary Reference Intakes, S259
- DIAMOND trial, S8, S218
- digital health technology, **S120**
- dipeptidyl peptidase 4 (DPP4) inhibitors, S30, S131, S147, S148, S149, S152, S173, S177, S222, S270
- disordered eating behavior, S53, S71, S80, S81, **S83–S84**, S233, S234–S235, S246
- do-it-yourself systems, **S120**
- domperidone, S209
- Dose Adjusted for Normal Eating (DAFNE), S106
- DRCR Retina Network, S205
- driving, and diabetes, S280
- droxidopa, S208
- dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, S7, S44, S60, S131, S146, S152
- DUAL-VIII trial, S154
- dulaglutide, S146, S148, S151, S152, S174, S181, S182
- duloxetine, S208
- dyslipidemia, S12, S25, S27, S44, S45, S53, S77, S132, S158, S159, S169, S171, S203, S206, S207, S220, S231, S232, **S238**, S239, S243, **S245**
- e-cigarettes, S239, S246, **S79**
- eating disorders, S71, **S83–S84**, S235
- eating patterns, S6, S42, S50, S59, S71, S72, **S73**, S74, S75, S81  
disrupted, S83, S84
- education, *see also* diabetes self-management  
education and support (DSMES).  
on device use, **S112**  
patient, **S210–S211**  
preconception, S255, S256  
staff, in rehabilitation and LTC settings, S224–S225
- electrical stimulation, gastric, S209, S212
- ELIXA trial, S174, S175, S181
- EMPA-REG OUTCOME trial, S177, S178, S179, S182, S197
- empagliflozin, S151, S152, S177, S178, S179, S180, S181, S182, S183, S189
- EMPEROR-Preserved trial, S180, S182
- EMPEROR-Reduced trial, S180, S182
- employment, diabetes and, S280
- enalapril, S208
- end-of-life care, **S219**, S223, **S225–S226**
- enteral/parenteral feedings, S270, S271, **S272**
- erectile dysfunction, S207, **S209**
- ertugliflozin, S152, S178, S180, S181, S270
- erythromycin, S209
- erythropoietin therapy, A1C and, S21, S22, S219
- estimated average glucose (eAG), S98
- ETDRS study, S205
- Ethnicity, S24, S25, **S27–S28**, S61, S118, S131  
effect on A1C, S22
- evidence-grading system, S3
- evolocumab, S168
- EXAMINE trial, S173, S182
- exenatide, S148, S148, S152, S174, S181, S182, S243
- exercise. *see* physical activity.
- exocrine pancreas diseases, S19, **S32**
- EXSCCEL trial, S174, S175, S181
- eye exam, comprehensive, S204, S240
- ezetimibe, S7, S166, S167, S168, S178  
statins and, **S168**, S170
- family history, S23, S25, S27, S29, S30, S32, S57, S83, S159, S171, S240, S242
- fasting plasma glucose (FPG) test, S20, S21, S22, S25, S28, S150
- fats, dietary, S9, S72, **S75**, S136, S238, S245, S257, S259
- FDA standards, for glucose meters, S113
- fenofibrate, S169, S170, S206
- fibrate, S232, S245  
plus statin therapy, S169, **S170**
- fibrosis-4 index risk calculator, S6, S58
- FIDELIO-DKD trial, S183, S198
- FIGARO-DKD trial, S183, S198, S199
- finerenone, S7, S176, **S183**, S198–S199
- FLOW trial, S197
- fluvastatin, S167
- food insecurity, S13–S14
- foot care, S8, S206, **S209–S212**, S240
- footwear, S78, S209, S211
- FOURIER trial, S168
- fractures, S148, S161, S177, S222, S223
- gastrectomy, vertical sleeve, S135–S136
- gastric aspiration therapy, S132
- gastric bypass, Roux-en-Y gastric, S135–S136
- gastric electrical stimulation, S209
- gastrointestinal neuropathies, **S207**
- gastroparesis, S207, **S208–S209**
- gemfibrozil, S170
- genetic testing, S30–S31, S58
- genitourinary disturbances, **S207**
- gestational diabetes mellitus (GDM), S9, S19, S24, S25, S27, **S32–S35**, S43, S44, S254, **S258–S260**, **S261–S262**  
definition, S32–S33  
diagnosis, S33–S35  
initial testing, S261–S262  
insulin, S260  
management of, **S258–S260**  
medical nutrition therapy, S259  
metformin, S259  
one-step strategy, S33–S34  
pharmacologic therapy, S259  
physical activity, S259  
postpartum care, S261–S263  
recommendations, S32  
screening and diagnosis, S33–S35  
sulfonylureas, S259  
two-step strategy, S34–S35
- glargine, S141, S144, S151, S152, S153, S154, S222
- glimepiride, S148, S152, S173, S177
- glipizide, S148, S152, S222
- glomerular filtration rate, S8, S30, S53, S75, S146, S147, S148, S165, S173, S175, S176, S179, S191–S192, **S193**, S222, S240, S244
- glucagon, S32, S104, **S105–S106**, S150
- glucagon-like peptide 1 receptor agonists (GLP-1 RA), S44, S102, S131, S134, S136, S142, S143, S147, S148, S150, S152, S172, S173, S175, S180, S181, S192, S196, S203, S242, S243, S270
- glucocorticoid therapy, S19, **S272–S273**
- glucose, for hypoglycemia, S104, S105
- glucose meters, S112–S114  
counterfeit strips, S113  
inaccuracy, S114  
interfering substances, S114  
optimizing use of, S113–S114  
oxygen, S114  
standards, S13  
temperature, S114
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S21, S22, S99
- glucose-lowering therapy, S7  
cardiovascular outcomes, S176  
choice of, S146  
for obesity and weight management, S131  
heart failure and, S181–S182  
in chronic kidney disease, S196–S198  
in hospitalized patients, **S268–S269**  
noninsulin, S152
- glulisine, S153, S222
- glyburide, S148, S152, S222, S258, S259
- glycemic control  
assessment of, **S98–S101**  
physical activity and, S78
- glycemic goals. *see also* glycemic targets, **S101–S104**
- glycemic targets, S6, **S97–S110**  
A1c and BGM correlation, S98  
A1c and cardiovascular disease outcomes, S102–S103  
A1c differences in ethnic groups and children, S98–S99  
A1c limitations, S98  
continuous glucose monitoring, **S100–S101**  
in diabetic kidney disease, S195  
goals, **S101–S104**  
in hospitalized patients, **S268–S269**  
hypoglycemia, **S104–S106**  
individualization of, S102, S103  
intercurrent illness, **S106**  
in older adults, S219–S221  
in pediatric type 1 diabetes, S235–S237  
in pediatric type 2 diabetes, S241–S242  
recommendations, S101  
setting and modifying A1C goals, S103–S104
- glycemic treatment, S7, **S140–S157**
- guanfacine, S208
- health literacy, S14–S15
- health numeracy, S12, S14–S15, S49, S50, S71, S75
- hearing impairment, S55
- heart failure, S7, S30, S50, S51, S54, S60, S77, S103, S129, S142, S146, S158–S159, S161, S175, S177, S180–S183
- hemodialysis, A1C and, S21, S219
- hemoglobinopathies, A1C on, S22, S28, S33, S41
- hepatitis B, **S54–S55**, S56
- hepatitis B vaccines, **S54–S55**, S195, S256
- hepatitis C infection, S256
- hepatitis, autoimmune, S23, S56, S237
- homelessness, S13, **S14**, S234, S246
- hospital care, S9, **S267–S278**  
care delivery standards, **S267–S268**

- continuous glucose monitoring, **S269**  
 diabetes care specialists in, **S268**  
 diabetic ketoacidosis, **S273**  
 enteral/parenteral feedings, **S272**  
 glucocorticoid therapy, **S272–S273**  
 glucose-lowering treatment in, **S269–S270**  
 glycemic targets in, **S268–S269**  
 hyperosmolar hyperglycemic state, **S273**  
 hypoglycemia, **S270–S271**  
 insulin therapy, **S269–S270**  
 medical nutrition therapy in, **S271–S272**  
 medication reconciliation, **S274**  
 noninsulin therapies, **S270**  
 perioperative care, **S273**  
 preventing admissions and readmissions, **S274**  
 self-management in, **S272**  
 standards for special situations, **S272–S273**  
 structured discharge communication, **S274**  
 transition to ambulatory setting, **S273–S274**
- HOT trial, **S161**  
 housing insecurity, **S13, S14**  
 HPS2-THRIVE trial, **S170**  
 human immunodeficiency virus (HIV), **S19, S21, S22, S24, S28, S207, S256**  
 human papilloma virus (HPV) vaccine, **S55**  
 human regular insulin, **S151, S152, S153, S272, S273**  
 hybrid closed-loop systems, **S119**  
 hydrogel, oral, **S132**  
 hyperbaric oxygen therapy, **S8, S211, S212**  
 hyperglycemia, **S5, S7, S9, S14, S20, S21, S22, S23, S27, S28, S29–S30, S32, S33, S34, S45, S46, S57, S59, S61, S74, S76, S83, S99, S101, S104, S106, S112, S113, S116, S132, S135, S141, S143, S149, S150, S151, S182, S193, S204, S218, S219, S220, S225, S226, S233, S234, S236, S242, S245, S254, S256, S257, S258, S267, S268, S269, S270, S271, S272, S273, S274**  
 Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, **S33, S34, S257**  
 hyperosmolar hyperglycemic state, **S106, S219, S242, S273**  
 hypertension, **S7, S9, S12, S24, S25, S27, S44, S54, S75, S78, S133, S159–S165, S171, S176, S191, S193, S196, S199, S204, S208, S216, S220, S225, S231, S232, S238, S240, S244, S245, S254, S256, S258, S259, S260, S261**  
 hypertriglyceridemia, **S75, S140, S149, S169**  
 hypoglycemia, **S6, S7, S8, S14, S31, S51, S54, S72, S76, S104–S106**  
   CGM technology in prevention of, **S106**  
   classification, **S104, S105**  
   in hospitalized patients, **S270–S271**  
   in older adults, **S57, S217–S218**  
   postbariatric, **S132, S136**  
 prevention, **S75, S78, S106**  
   risk, **S54**  
   treatment, **S105–S106**  
 hypogonadism, **S209**  
 hypokalemia, **S165, S192, S194**
- inlisiran, **S7, S168–S169**  
 incretin-based therapies, **S84, S181, S222–S224**  
 Indian Diabetes Prevention Program (IDPP-1), **S44**  
 infections, **S51, S62, S128, S144, S148, S207, S223, S273**  
   diabetic foot, **S203–S204**  
 influenza vaccines, **S53–S54, S55**  
 inhaled insulin, **S117, S141, S143, S148, S153–S154**  
 injection techniques, **S118, S142**  
 insulin analogs, in type 1 diabetics, **S119, S140, S141, S144, S148, S149, S151, S152, S154, S224, S236, S270, S273**  
 insulin delivery, **S112, S117**  
   automated systems, **S118, S119**  
   do-it-yourself closed-loop systems, **S120**  
   injection techniques, **S118, S142**  
   intravenous, transitioning to subcutaneous, **S270**  
   pens and syringes, **S117–S118**  
   pumps, **S118–S119**  
 insulin pump therapy, **S118–S119**  
 insulin resistance, **S5, S19, S20, S24, S25, S26, S27, S28, S29, S44, S45, S58, S59, S77, S86, S153, S245, S256, S257, S258, S259, S260, S261**  
 insulin secretagogues, **S54, S72, S78, S105, S131, S222**  
 insulin therapy  
   access and affordability, **S279**  
   dosing algorithms using machine learning, **S9, S268**  
   in adults with type 1 diabetes, **S140–S142**  
   in adults with type 2 diabetes, **S142–S154**  
   basal, **S9, S113–S114, S116, S119, S140, S141, S150, S151, S152, S153, S154–S145, S222, S224, S226, S233, S269, S270, S271, S272, S273**  
   combination injectable, **S154**  
   concentrated insulins, **S152–S153**  
   in hospitalized patients, **S269–S270**  
   inhaled insulin, **S117, S141, S143, S148, S153–S154**  
   monitoring for intensive regimens, **S113**  
   in older adults, **S221–S224**  
   prandial, **S7, S113, S141–S142, S143, S150, S151–S152, S154, S222, S233, S234, S243, S270, S271**  
   insulin:carbohydrate ratio (ICR), **S144, S145**  
   integrated CGM devices, **S6, S115**  
   intensification, of therapy, **S141, S143, S149, S151, S154, S176**  
   intermittent fasting, **S6, S73**  
   intermittently scanned CGM devices, **S106, S114–S115, S116, S235, S236, S241, S258**  
 International Association of the Diabetes and Pregnancy Study Groups (IADPSG), **S33–S36**  
 International Diabetes Closed Loop (iDCL) trial, **S141**  
 islet transplantation, **S32, S105, S142**  
 isradipine, **S208**
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, **S194**  
 ketoacidosis, diabetic, **S20, S60, S61, S77, S81, S106, S116, S141, S142, S148, S177, S224, S233, S243, S256, S260, S273**  
 kidney disease. *see* chronic kidney disease
- Kumamoto study, **S101**
- language barriers, **S13**  
 latent autoimmune diabetes in adults (LADA), **S20**  
 Latino population, **S13**  
 LEADER trial, **S174–S175, S180, S197**  
 lifestyle behavior changes  
   delivery and dissemination of, **S43**  
   for diabetes prevention, **S42–S43**  
   for hypertension, **S163**  
   for lipid management, **S165–S166**  
   for weight management, **S59, S71, S121**  
   in older adults, **S220–S221**  
   in pediatric type 1 diabetes, **S233–S234**  
   in pediatric type 2 diabetes, **S7, S242**  
   in pregnancy, **S9, S163**  
   to reduce ASCVD risk factors, **S176**  
   with NAFLD, **S6**  
 linagliptin, **S148, S152, S173, S177, S182**  
 lipase inhibitors, **S133**  
 lipid management, **S165–S166, S225**  
 lipid profiles, **S53, S166, S231, S232, S238, S239**  
 liraglutide, **S44, S60, S132, S134, S142, S148, S151, S152, S153, S154, S174, S180, S182, S197, S243, S244**  
 lispro, **S141, S153, S222**  
 lixisenatide, **S148, S152, S153, S154, S174, S181, S182**  
 long-acting insulin, **S141, S143, S145, S149, S150, S151, S153, S224, S234, S236, S242, S243, S254, S255, S262, S272, S273**  
 Look AHEAD trial, **S60, S61, S130–S131, S176, S221**  
 loss of protective sensation, **S8, S206, S209, S210**  
 lovastatin, **S167**
- machine learning, dosing algorithms using, **S9, S268**  
 macular edema, diabetic, **S204–S206**  
 maternal history, in screening children/  
   adolescents, **S25**  
 maturity-onset diabetes of the young (MODY), **S19, S20, S30–S31, S230, S241**  
 meal planning, **S6, S73–S75, S256**  
 Medicaid expansion, **S13**  
 medical devices, for weight loss, **S132**  
 medical evaluation, **S5, S51–S62**  
   autoimmune diseases, **S56**  
   cancer, **S57–S58**  
   cognitive impairment/dementia, **S57**  
   immunizations, **S51, S53–S55**  
   nonalcoholic fatty liver disease, **S57–S60**  
   obstructive sleep apnea, **S60**  
   periodontal disease, **S60**  
   recommendations, **S48**  
 medical nutrition therapy, **S69, S70–S76**  
   alcohol, **S76**  
   carbohydrates, **S73–S75**  
   eating patterns and meal planning, **S73**  
   fats, **S75**  
   goals of, **S71**  
   in hospitalized patients, **S271–S272**  
   micronutrients and supplements, **S75–S76**  
   nonnutritive sweeteners, **S76**  
   protein, **S75**  
   sodium, **S75**  
   weight management, **S71**  
 Mediterranean diet, **S42, S57, S59, S71, S72, S73, S74, S75, S166**

- meglitinides, S54, S152  
 mental health referrals, S8, S54, S71, S79, S89, S81, S82, S83, S132, S234–S235, S246  
 mental illness, serious, S81, **S84**  
 metabolic surgery, S71, S81, S128, S129, S130, **S132–S136**, **S243–S244**  
 metformin, S30, S31, S32, S43–S44, S53, S62, S75, S102, S103, S131, S142, S143, S146, S148, S149, S151, S152, S154, S173, S174, S176, S178, S182, S184, S196, S217, **S221**, S222, S232, S242, S243, S245, S258, **S259**, S260, S261, S262, S273  
 metoclopramide, S209  
 metoprolol, S208  
 micronutrients, S71, S72, **S75–S76**  
 microvascular complications, S11, S27, S31, S32, S45, **S78**, S99, **S101–S102**, S104, S141, S142, S159, S206, S219, **S239–S240**, S255  
 midodrine, S208  
 miglitol, S152  
 migrant farmworkers, S13  
 mineralocorticoid receptor antagonist therapy, S8, S164, S165, S183, S192, S193, S194, S196, **S198–S199**  
 monogenic diabetes syndromes, S19, **S30–S32**  
 multiple daily injections (MDI), S53, S113, S115, S116, S118, S119, S143, S144, S145, S243  
 myasthenia gravis, S23, S56, S237
- naltrexone/bupropion ER, S132, S133  
 nateglinide, S44, S152  
 National Diabetes Data Group, S35  
 National Diabetes Prevention Program, S43  
 National Health and Nutrition Examination Survey (NHANES), S11, S21, S34, S241  
 neonatal diabetes, S19, **S30**  
 nephrologist, referral to, S8, S192, S193, S194, **S199**  
 nephropathy, diabetic, S27, S165, S173, S175, S179, S197, S203, S209, S231, S232, S239, **S244**, S256  
 neurocognitive function, **S217**  
 neuropathic pain, S8, S208  
 neuropathy, diabetic, S8, S44, S54, S101, S149, **S206–S209**, S211, S231, S232, **S240**, **S244**, S256
  - autonomic, S8, **S78**, S160, **S207**, S273
  - cardiac autonomic, S206, **S207**
  - gastrointestinal, **S207**
  - genitourinary disturbances due to, **S207**
  - peripheral, S56, **S78**, S119, **S206–S207**, S210
- new-onset diabetes after transplantation (NODAT), S29  
 niacin + statin therapy, S169, **S170**  
 nonalcoholic fatty liver disease (NAFLD), S6, S53, **S57–S60**, S256  
 nonalcoholic steatohepatitis (NASH), S6, S57–S60, S148  
 noninsulin treatments, S30, S106, S112, **S113–S114**, S116, **S142**, S149, S152, S221, S222, S223, S258, **S270**  
 noninsulin-dependent diabetes. *see* type 2 diabetes.  
 nonnutritive sweeteners, S72, **S76**  
 NPH insulin, S141, S145, S148, S149, S150, S151, S152, S153, S155, S222, S224, S270, S272, S273  
 nucleoside reverse transcriptase inhibitors, S22  
 nursing homes, **S224–S225**  
 nutrition
  - for diabetes prevention/delay, S42–S43
  - nutrition therapy. *see* medical nutrition therapy.
- obesity, S7, **S128–S139**
  - assessment, **S129**
  - medical devices for weight loss, **S132**
  - metabolic surgery, **S132**, **S135–S136**
  - nutrition, physical activity, and behavioral therapy, **S129–S131**
  - pharmacotherapy, **S131–S132**, 133–134
  - screening asymptomatic children/adolescents, S24, S25
- obstructive sleep apnea, S53, **S58**, S86, S232, **S245**  
 ODYSSEY OUTCOMES trial, S168  
 older adults, S7, **S216–S229**
  - end-of-life care, S225–S226
  - hypoglycemia, S217–S218
  - lifestyle management, S220–S221
  - neurocognitive function, S217
  - pharmacologic therapy, S221–S224
  - in skilled nursing facilities and nursing homes, S224–S225
  - treatment goals, S218–S220
  - with type 1 diabetes, S224
- one-step strategy, for GDM, S33–S34  
 opioid antagonist/antidepressant combination, S133  
 ophthalmologist, referral to, S78, S204, S205  
 oral agents, S113, S114, S149, S151, S225, S259  
 oral glucose tolerance test (OGTT), S20, S21, S25, S28, S29, S30, S31, S33, S34, S35, S258, S262  
 organ transplantation, posttransplantation diabetes mellitus, S19, S29–S30  
 orlistat, S132, S133  
 orthostatic hypotension, **S208**  
 overweight people, screening asymptomatic, S24 adults, S24  
 children/adolescents, S24, S25  
 oxygen, glucose monitors and, S114  
 oxygen therapy
  - hyperbaric, S8, S211, S212
  - topical, S8, S209, S211, S212
- P2Y12 receptor antagonists, S170, **S172**  
 palliative care, S219, S224, S225  
 pancreas transplantation, **S142**, S146  
 pancreatectomy, S32, S119  
 pancreatic diabetes, S19, **S32**  
 pancreatitis, S20, S32, S134, S148, S169, S181, S245  
 pancreoprivic diabetes, S32  
 pens, insulin, S112, **S117–S118**  
 periodontal disease, S28, S54, **S60**  
 perioperative care, S135, **S273**  
 peripheral arterial disease, S210  
 peripheral neuropathy, S56, **S78**, S119, **S206–S207**, S210  
 pernicious anemia, S23, S56, S129  
 person-centered care, S69, S101, S142, S143
  - collaborative care, S10, **S49–S51**, S79
  - goals, **S45–S46**
- pharmacologic approaches. *see also* specific medications, medication classes.
  - for adults with type 1 diabetes, **S140–S142**
  - for adults with type 2 diabetes, **S142–S154**
  - for cardiovascular and renal disease, S54, S176–S185, S196–S197
  - for hypertension, S163–S165
  - for lipid management, S166–S170
  - for neuropathic pain, S8, S208
  - for obesity, S131–S132
  - for pediatric type 2 diabetes, **S242–S243**
  - for smoking cessation, S79
  - in older adults, **S221–S224**
  - in pregnancy, **S259–S260**
  - in prediabetes, **S43–S44**
  - interfering substances for glucose meter readings, S114
    - to glycemic treatment, S7, S54, **S140–S157**
  - phentermine, S44, S132, S133
  - phentermine/topiramate ER, S132, S133, S244
  - phosphodiesterase type 5 inhibitors, S209
  - photocoagulation surgery, S205, S206
  - physical activity, S10, S12, S15, S27, S28, S42, **S43**, S50, **S76–S78**, **S130–S131**, S150, S176, S208, S221, S241, S242
    - for depression, S83
    - for diabetes prevention, **S43**
    - glycemic control and, **S78**, S106
    - impact on blood glucose, S112, S113, S114, S119
    - in children with type 1 diabetes, **S233–S234**
    - in pregnancy, **S259**
    - with microvascular complications, **S78**
    - pre-exercise evaluation, **S78**
  - pioglitazone, S5, S6, S44, S45, S59–S60, S148, S152  
 PIONEER-6 trial, S174–S175, S180  
 pitavastatin, S167  
 Plenity, S132  
 pneumococcal pneumonia vaccines, S6, **S54**  
 point-of-care assays
    - A1c, S5, S21, S98
    - blood glucose monitoring, S269
  - polycystic ovarian syndrome, S24, S25, S27, S232, **S245**, S256, S258, S259  
 population health, S5, **S10–S18**
    - care delivery systems, S11
    - care teams, S12
    - chronic care model, S11
    - recommendations, S10
    - social context, S13–S15
  - postbariatric hypoglycemia, S132, S136  
 postpancreatitis diabetes mellitus (PPDM), S32  
 postpartum care, in diabetic women, **S261–S262**  
 postpartum state, A1C in, S22  
 posttransplantation diabetes mellitus, S19, **S29–S30**  
 pramlintide, S142, S152, S209  
 prandial insulin, S7, S113, S141–S142, S143, S150, **S151–S152**, S154, S222, S233, S234, S243, S270, S271  
 pravastatin, S167  
 prediabetes, **S24–S25**
    - criteria defining, S25
    - diagnosis, S25
    - prevention of vascular disease and mortality, **S44–S45**
    - screening, S5, S24–S25
  - preeclampsia, in women with diabetes, S33, S34, S163, S254, S255, S257, S258, S259  
 aspirin and, S260–S261  
 pregabalin, S132, S208  
 pregnancy, S8, S9, S19, **S254–S266**
    - A1C and, S21, S22, S257–S258
    - continuous glucose monitoring in, S258
    - diabetes in, S254–S255
    - drug considerations in, **S261**
    - eye exams during, S255

- gestational diabetes mellitus (GDM), S9, S19, S24, S25, S27, **S32–S35**, S43, S44, S254, **S258–S260**, **S261–S262**
- glucose monitoring in, S257
- glycemic targets in, **S256–S258**
- insulin physiology in, S257
- metformin in, S259
- pharmacologic therapy, S259
- physical activity in, S259
- postpartum care, **S261–S262**
- pre-existing type 1 and 2 diabetes in, S255, S256, S257, **S260**
- preconception care, **S255**, **S256**
- preconception counseling, **S254–S255**
- preeclampsia and aspirin, **S260–S261**
- real-time CGM device use in, **S116**
- retinopathy during, **S204–S205**
- sulfonylureas, S259
- prevention, type 2 diabetes, S5, S8, **S41–S48**
- lifestyle behavior change, **S42–S43**
- person-centered care goals, **S45–S46**
- pharmacologic interventions, **S43–S44**
- recommendations, S41, S42, S43–S44
- of vascular disease and mortality, **S44–S45**
- proliferative diabetic retinopathy, S78, S204, S205
- proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, S7, S166, S167, **S168**, S170
- protease inhibitors, A1C and, S22
- protein intake, **S75**, S193, S195, S220, S244
- psychosocial care, S6, S51, **S79–S86**
- anxiety disorders, S82
- cognitive capacity/impairment, S84–S86
- depression, S82–S83
- diabetes distress, S81–S82
- disordered eating behavior, S83–S84
- in pediatric type 1 diabetes, S234–S235
- in pediatric type 2 diabetes, S246
- in pregnancy, S261
- referral to mental health specialist, S80–S81
- serious mental illness, S86
- sleep health, S86
- pumps, insulin, S112, S117, **S118–S120**
- do-it-yourself closed-loop system, S120
- in type 2 and other types of diabetes, S119
- in youth, S119
- sensor augmented, S119
- quality improvement, S5, S13, S267, S270
- RAAS inhibitors, S195, **S196**
- Race, S24, S25, S70, S105, S118, S131, S159, S173, S174, S178, S193
- effect on A1C, S21, S22
- rapid-acting insulin analog, S105, S118, S119, S140, S141, S143, S145, S150, S152, S153, S222, S225, S258, S271, S272, S273
- real-time CGM devices, S7, S106, S114–S115, S116, S136, S235, S236, S241, S256, S258, S269
- REDUCE-IT trial, S75, S169
- referrals, S58, S70, S260
- for cognitive testing, S84, S219
- for community screening, S28
- for comprehensive eye exam, S204, S240, S245, S255
- for local community resources, S13
- for DSME, S54, S70, S217
- for tobacco cessation, S44
- from dentist to primary care, S28
- to behavioral health provider, S217
- to foot care specialist, S8, S211
- to gastroenterologist, S245
- to mental health professional, S8, S80–S81
- to nephrologist, S8, S192, S194, **S199**, S244
- to neurologist, S206, S231
- to sleep specialist, S87, S245
- to registered dietitian nutritionist, S43, S255, S257, S274
- registered dietitian nutritionist (RDN), S43, S255, S257, S274
- reimbursement, for DSMES, S69, **S70**
- repaglinide, S29, S152
- retinopathy, diabetic, S8, S27, S54, S58, S77, **S78**, S101, S119, S161, S193, S194, S198, **S203–S206**, S209, S231, S232, S237, S240, S244–S245, S255, S256, S260
- REWIND trial, S175, S181
- risk calculator, for ASCVD, S6, **S159**
- risk management
- cardiovascular disease, S7, **S158–S190**
- chronic kidney disease, S8, **S191–S202**
- risk, screening for, S23–S28
- rivaroxaban, S170, S172
- rosiglitazone, S148
- Roux-en-Y gastric bypass, S135
- SAVOR-TIMI trial, S173, S182
- saxagliptin, S148, S152, S173, S182, S270
- schizophrenia, S84
- schools
- device use in, **S112**
- diabetes care in, **S234**
- pediatric type 1 diabetes and, S233
- screening
- for cardiovascular disease, **S159–S160**
- in children/adolescents, S28
- community, S28
- in dental practices, S28
- for gestational diabetes mellitus, S28, **S32–S33**
- in individuals with HIV, S28
- medications, S28
- for neuropathy, S240
- for prediabetes and type 2 diabetes, S27–S28
- testing interval, S28
- for type 1 diabetes, S23–S24
- for type 2 diabetes, **S240–S241**
- seasonal farmworkers, S13
- self-monitoring of blood glucose (SMBG). *see* blood glucose monitoring (BGM)
- semaglutide, S44, S60, S132, S134, S146, S148, S149, S151, S152, S174–S175, S180–S181, S182, S197, S222
- sensor-augmented pumps, S8, S106, S118, **S119**, S141, S144, S218, S236, S260
- sensory impairment, S53, S209, S210
- setmelanotide, S132
- sexual dysfunction, S207
- sickle cell disease, A1C and, S21, S22
- simvastatin, S167, S168, S170
- sitagliptin, S148, S152, S173, S182
- skilled nursing facilities, S223, **S224–S225**
- sleep health, S86
- smart pens. *see* connected insulin pens
- smoking cessation, S45, S51, **S79**, S239
- social capital, S15
- social context, S13–S15
- social determinants of health (SDOH), S7, S11–S13, S15, S70, S80, S147
- sodium intake, S72, S74, **S75–S76**, S163
- sodium–glucose cotransporter 2 (SGLT2) inhibitors, S102, S103, S142, S148, S149, S151, S152, S154, S158, S159, **S177–S180**, S181, S182, S183, S184, S194, S196, S197, S198, S218, **S224**, S270, S273
- SOLOIST-WHF trial, S183
- sotagliflozin, S180, S182, S183
- SPRINT trial, S160, S161, S162
- staging
- of diabetic kidney disease, S54, **S194**
- of type 1 diabetes, S20
- statin therapy, S5, S7, S44, S45, S75, **S166–S169**, S173, S174, S176, S178, S220, S231, S232, S238, S239, S245
- diabetes risk with, **S170**
- with bempedoic acid, **S169**
- with fibrates, S169, **S170**
- with niacin, S169, **S170**
- statins, **S57**
- sulfonylureas, S8, S14, S30, S31, S99, S146, S148, S152, S154, S221, S222, S224, **S259**
- supplements, dietary, S72, **S75–S76**, S130, S131
- surveillance
- for foot problems, S209–S211
- of chronic kidney disease, S194–S195
- SUSTAIN-6 trial, S174–S175, S180, S197
- sweeteners, nonnutritive, S72, **S76**
- sympathomimetic amine anorectics, S133
- in combination with antiepileptic, S133
- syringes, insulin, S117–S118
- tapentadol, S208
- technology, diabetes, S6, S12, **S111–S127**
- blood glucose monitoring, **S112–S114**
- continuous glucose monitoring devices, **S114–S117**
- general device principles, **S111–S112**
- insulin delivery, **S117–S121**
- TECOS trial, S173, S182
- TEDDY study, S24
- telehealth, S11
- temperature
- of glucose monitor, S114
- perception of, S206, S209, S210
- testing interval, S28
- testosterone, low, in men, S44
- tetanus, diphtheria, pertussis (TDAP) vaccine, S55
- thiazide-like diuretics, S164, S165, S196
- thiazolidinediones, S30, S44, S131, S148, S183, **S222**
- thyroid disease
- autoimmune, S31, S56
- in pediatric type 1 diabetes, S231, **S237**
- time-restricted eating, S6, S73
- tirzepatide, S7, S44, S60, S131, S146, S152
- tobacco cessation, S44, S68, **S79**, S239, S246
- training
- blood glucose awareness, S82
- on device use, S112
- tramadol, S208
- transfusion, A1C and, S21
- transition
- from hospital to ambulatory setting, S270, **S273–S274**
- from pediatric to adult care, S230, **S246**
- transplantation
- islet, S105, **S142**, S146

- liver, S58  
organ, post-transplant diabetes mellitus after, S19, S29–S30  
pancreas, **S142**, S146  
renal, S146, S57, S173, S174, S180, S182, S197
- tricyclic antidepressants, S8, S131, S207, **S208**, S209
- TWILIGHT trial, S172
- two-hour plasma glucose (2-h PG) test, S20, S21, S22, S25, S31, S33, S34
- two-step strategy, for GDM, S34–S335
- type 1 diabetes, S8, S9, S12, S13  
A1C and cardiovascular disease outcomes in, S103  
beta-cell replacement therapy, S142, S146, S175  
in children/adolescents, **S233–S240**  
classification, **S19–S20**  
diagnosis, **S22–S24**  
idiopathic, S23  
immune-mediated, S23  
in hospitalized patients, S270  
insulin therapy, **S140–S142**  
noninsulin treatments, **S142**  
in older adults, S8, S224  
peripheral neuropathy in, S206  
pregnancy in women with preexisting, S9, S205, S255, S257, S258, **S260**  
retinopathy in, S8, 204  
screening, S23–S24  
staging, S20
- subcutaneous insulin regimens, S112, S114–S115, S140, S144–S145, S148  
surgical treatment, **S142**
- type 2 diabetes  
A1C and cardiovascular disease outcomes in, S103  
in children/adolescents, **S240–S246**  
classification, **S19–S20**  
combination therapy, S7, S143, S144, S146, S147, S149, S150–S151, S154, S161, S168, S168–S169, S169–S170, S208, S222  
initial therapy, S119, S238  
insulin pump use in, S119  
obesity and weight management, S6, S27, S59, S60, S120, **S128–S136**, S244  
pharmacologic treatment in adults, **S142–S154**  
pregnancy in women with preexisting, **S260**  
prevention or delay, **S41–S48**  
retinopathy in, S204  
risk test for, S26  
screening in asymptomatic adults, S27–S28  
screening in children/adolescents, S4, S28
- type 3c diabetes, S32
- UK Prospective Diabetes Study (UKPDS), S101, S102, S103, S104, S176
- ulcers, foot, S53, S78, S206, **S209–S212**  
ultra-rapid-acting insulin analogs, S143, S145
- vagus nerve stimulator, S132  
vascular disease, S176, S209  
prevention of, in prediabetes, **S44–S45**  
VERIFY trial, S149  
vertical sleeve gastrectomy, S135  
VERTIS CV trial, S178, S179, S180  
Veterans Affairs Diabetes Trial (VADT), S101, S102, S103, S218  
vildagliptin, S149  
vitamin D supplementation, S44, S72, S76, S131  
VOYAGER-PAD trial, S172
- weight loss surgery. *see* metabolic surgery.  
weight loss/management, **S70–S76**, S163, S165, S176, S208, S220–S221  
in diabetes prevention, S6, S9, S28, S29, S42–S43, S44, S45, S76  
in type 1 diabetes, S20  
in type 2 diabetes, S6, S27, S59, S60, S120, **S128–S136**, S244
- well-being, S6, S12, **S68–S97**, **S236**
- whites, non-Hispanic, S22, S25, S28, S61, S77, S98, S160, S173, S174, S178
- WISDM trial, S8, S218
- zoster vaccine, S55